BATM Advanced Communications Ld Appointment of Non-Executive Director (1871I)
13 Aprile 2022 - 8:01AM
UK Regulatory
TIDMBVC
RNS Number : 1871I
BATM Advanced Communications Ld
13 April 2022
LEI: 213800FLQUB9J289RU66
13 April 2022
BATM Advanced Communications Limited
("BATM" or "the Group")
Appointment of Non-Executive Director
BATM (LSE: BVC; TASE: BVC), a leading provider of real-time
technologies for networking solutions and medical laboratory
systems, is pleased to announce the appointment of Dr. Avigdor
Shafferman as a Non-Executive Director of the Company with
immediate effect.
Dr. Avigdor Shafferman, aged 75, had an established career at
the Israel Institute for Biological Research, a leading
governmental applied research institute specialising in the fields
of biology, medicinal chemistry and environmental sciences, where
he worked for almost 40 years. Most recently, from 1995 until his
retirement in 2013, he was General Director of the organistion.
Other roles have included serving as a visiting professor in the
University of California, San Diego at the biology department as
well as a visiting senior research scientist at various leading
research institutions in the United States in various medical
areas, including vaccines. Dr. Shafferman holds a Ph.D. in physical
chemistry from the Hebrew University of Jerusalem.
Previously, Dr. Shafferman served as an external director of the
Group (as defined under Israeli law) from February 2015 to February
2018. External directors under Israeli law are appointed for terms
of three years. With his new appointment as a Non-executive
Director, Dr. Shafferman will be subject to annual re-election at
the Group's annual general meeting.
Dr. Gideon Chitayat, Chairman of BATM, said: "On behalf of the
Board, I would like to welcome Avigdor back to BATM. He made an
excellent contribution to our business previously and we look
forward to once again being able to leverage his wealth of
knowledge and experience as we continue to advance our leading-edge
medical diagnostics solutions."
There is no further information required to be disclosed in
relation to Dr. Shafferman pursuant to Listing Rule 9.6.13 and Dr.
Shafferman does not have any beneficial interest in BATM's ordinary
shares.
Enquiries:
BATM Advanced Communications
Dr Zvi Marom, Chief Executive Officer +972 9866 2525
Moti Nagar, Chief Financial Officer
Shore Capital
Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory) +44 20 7408 4050
Luther Pendragon
Harry Chathli, Claire Norbury +44 20 7618 9100
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABRGDSBUBDGDD
(END) Dow Jones Newswires
April 13, 2022 02:01 ET (06:01 GMT)
Grafico Azioni BATM Advanced Communicat... (AQSE:BVC.GB)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni BATM Advanced Communicat... (AQSE:BVC.GB)
Storico
Da Nov 2023 a Nov 2024